Xponance Inc. Has $260,000 Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Xponance Inc. increased its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCIGet Rating) by 13.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,601 shares of the biopharmaceutical company’s stock after purchasing an additional 666 shares during the period. Xponance Inc.’s holdings in Intra-Cellular Therapies were worth $260,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. US Bancorp DE increased its position in shares of Intra-Cellular Therapies by 93.8% in the second quarter. US Bancorp DE now owns 496 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 240 shares during the period. Assetmark Inc. increased its holdings in Intra-Cellular Therapies by 410.0% in the 2nd quarter. Assetmark Inc. now owns 510 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 410 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in shares of Intra-Cellular Therapies in the 3rd quarter valued at approximately $41,000. Northern Oak Wealth Management Inc. bought a new stake in shares of Intra-Cellular Therapies during the 2nd quarter worth approximately $51,000. Finally, Exchange Traded Concepts LLC lifted its holdings in shares of Intra-Cellular Therapies by 138.3% during the 2nd quarter. Exchange Traded Concepts LLC now owns 1,299 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 754 shares during the period. Institutional investors own 86.95% of the company’s stock.

Insider Activity

In other news, Director Joel S. Marcus sold 5,000 shares of the firm’s stock in a transaction on Monday, December 19th. The shares were sold at an average price of $50.82, for a total transaction of $254,100.00. Following the completion of the transaction, the director now owns 29,233 shares of the company’s stock, valued at $1,485,621.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Joel S. Marcus sold 5,000 shares of the firm’s stock in a transaction on Monday, December 19th. The shares were sold at an average price of $50.82, for a total transaction of $254,100.00. Following the completion of the transaction, the director now owns 29,233 shares of the company’s stock, valued at $1,485,621.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael Halstead sold 50,000 shares of the stock in a transaction on Thursday, December 1st. The stock was sold at an average price of $53.73, for a total transaction of $2,686,500.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 88,083 shares of company stock valued at $4,760,165. Insiders own 3.70% of the company’s stock.

Intra-Cellular Therapies Price Performance

Shares of NASDAQ:ITCI opened at $48.80 on Wednesday. The firm has a 50 day simple moving average of $51.77 and a 200 day simple moving average of $51.38. The company has a market cap of $4.62 billion, a price-to-earnings ratio of -14.70 and a beta of 1.18. Intra-Cellular Therapies, Inc. has a one year low of $38.51 and a one year high of $66.00.

Intra-Cellular Therapies (NASDAQ:ITCIGet Rating) last released its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.29. The firm had revenue of $71.87 million during the quarter, compared to the consensus estimate of $64.95 million. Intra-Cellular Therapies had a negative net margin of 158.39% and a negative return on equity of 45.52%. As a group, analysts expect that Intra-Cellular Therapies, Inc. will post -2.87 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ITCI. Canaccord Genuity Group upped their price target on shares of Intra-Cellular Therapies from $90.00 to $93.00 in a report on Friday, November 4th. Mizuho reissued a “buy” rating and issued a $72.00 price objective on shares of Intra-Cellular Therapies in a research note on Monday, October 3rd. Finally, StockNews.com raised shares of Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a research note on Friday, November 4th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $69.29.

Intra-Cellular Therapies Company Profile

(Get Rating)

Intra-Cellular Therapies, Inc, a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults.

Read More

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.